Sickle cell disease activates peripheral blood mononuclear cells to induce cathepsins k and v activity in endothelial cells
Autor: | Manu O. Platt, Philip M. Keegan, Sindhuja Surapaneni |
---|---|
Rok vydání: | 2011 |
Předmět: |
Article Subject
Cell Inflammation 030204 cardiovascular system & hematology Systemic inflammation Peripheral blood mononuclear cell 03 medical and health sciences 0302 clinical medicine Cathepsin K medicine Cathepsin V 030304 developmental biology Cathepsin 0303 health sciences business.industry lcsh:RC633-647.5 Cell Biology Hematology lcsh:Diseases of the blood and blood-forming organs Molecular biology 3. Good health medicine.anatomical_structure Immunology Tumor necrosis factor alpha medicine.symptom business Research Article |
Zdroj: | Anemia Anemia, Vol 2012 (2012) |
ISSN: | 2090-1275 |
Popis: | Sickle cell disease is a genetic disease that increases systemic inflammation as well as the risk of pediatric strokes, but links between sickle-induced inflammation and arterial remodeling are not clear. Cathepsins are powerful elastases and collagenases secreted by endothelial cells and monocyte-derived macrophages in atherosclerosis, but their involvement in sickle cell disease has not been studied. Here, we investigated how tumor necrosis alpha (TNFα) and circulating mononuclear cell adhesion to human aortic endothelial cells (ECs) increase active cathepsins K and V as a model of inflammation occurring in the arterial wall. ECs were stimulated with TNFα and cultured with peripheral blood mononuclear cells (PBMCs) from persons homozygous for sickle (SS) or normal (AA) hemoglobin. TNFα was necessary to induce cathepsin K activity, but either PBMC binding or TNFα increased cathepsin V activity. SS PBMCs were unique; they induced cathepsin K in ECs without exogenous TNFα (n=4,P<0.05). Inhibition of c-Jun N-terminal kinase (JNK) significantly reduced cathepsins K and V activation by 60% and 51%, respectively. Together, the inflammation and activated circulating mononuclear cells upregulate cathepsin activity through JNK signaling, identifying new pharmaceutical targets to block the accelerated pathology observed in arteries of children with sickle cell disease. |
Databáze: | OpenAIRE |
Externí odkaz: |